Michelle Dipp is a Co-Founder and Managing Partner at Biospring Partners. Michelle is passionate about life sciences and has over a decade of private equity and venture capital expertise. She currently serves on the Board of Directors of Biospring portfolio company, Abzena.
Prior to Biospring, Michelle was a Managing Director at General Atlantic where she launched their first life sciences investment platform and served as a member of the life sciences investment committee. Michelle led multiple investments in synthetic biology and served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.
Michelle co-founded and served as General Partner of Longwood Fund, a leading healthcare investment firm based in Boston.
Before joining Longwood, Michelle was a senior executive at GlaxoSmithKline’s (GSK) who acquired Sirtris Pharmaceuticals, Inc., where Michelle served as Vice President of Corporate Development.
Michelle began her investment career at the Wellcome Trust after completing her medical training. She holds a Bachelor of Medicine and Bachelor of Surgery from the University of Oxford Medical School and a Doctor of Philosophy in Human Physiology from the University of Oxford.
Being born and raised on the border in El Paso, Texas, Michelle cares deeply about her community. Michelle currently serves on the Trustee Advisory Board for Beth Israel Deaconess Medical Center; Advisory Board for the Women’s Foundation of Boston; Board of Directors for Life Science Cares; Rockefeller University Council; Advisory Council for the American Museum of Natural History; Co-Founding Member of the Bowman Fund, Brasenose College Boat Club, Oxford University; and a member of the World Economic Forum’s Young Global Leaders.